edited by Edward P. Gelmann, Charles L. Sawyers, Frank J. Rauscher III
Cambridge :
Cambridge University Press,
2014
xxi, 961 pages :
color illustrations ;
29 cm
Includes bibliographical references and index
Part 1.1. Analytical techniques: analysis of DNA -- Part 1.2. Analytical techniques: analysis of RNA -- Part 2.1. Molecular pathways underlying carcinogenesis: signal transduction -- Part 2.2. Molecular pathways underlying carcinogenesis: apoptosis -- Part 2.3. Molecular pathways underlying carcinogenesis: nuclear receptors -- Part 2.4. Molecular pathways underlying carcinogenesis: DNA repair -- Part 2.5. Molecular pathways underlying carcinogenesis: cell cycle -- Part 2.6. Molecular pathways underlying carcinogenesis: other pathways -- Part 3.1. Molecular pathology: carcinomas -- Part 3.2. Molecular pathology: cancers of the nervous system -- Part 3.3. Molecular pathology: cancers of the skin -- Part 3.14 Molecular pathology: endocrine cancers -- Part 3.5. Molecular pathology: adult sarcomas -- Part 3.6. Molecular pathology: lymphoma and leukemia -- Part 3.7. Molecular pathology: pediatric solid tumors -- Part 4. Pharmacologic targeting of oncogenic pathways
2
"The genomic era has allowed enormous strides in our understanding of the molecular changes that underlie malignant transformation. Mutations have been discovered that are critical drivers of large cross-sections of human cancers. These discoveries have allowed us to find drugs that target these drivers and make important strides in treatment. Genomics and high-throughput technologies have illuminated the complexity of cancer and the facility with which cancers adapt during their natural history. The field is evolving rapidly with new discoveries and new drugs reported monthly. This book is a timely foundation for understanding in context the origins of molecular oncology and its future directions. The content reviews available technologies for the analysis of cancer tissues and genes; summaries of key oncogenic pathways from a molecular perspective; the technologies, pathways and targeted therapies of a wide range of human malignancies; and new pharmacologic therapies that have a common mechanistic target"--
"This book was conceived more than five years before its publication date. It was intended to provide a resource that summarized technology, biochemistry, molecular pathophysiology, and targeted therapeutics. As contributors were being recruited and chapters written the field that was being described changed at an accelerating pace. It is a tribute to scientific progress that volumes like this one are out-of-date as they are published, but books like this are not meant to contain the most current laboratory discovery or report the most recent FDA approval"--